NervGen Pharma Corp.
NGEN
$2.13
-$0.06-2.74%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.87% | 8.77% | 18.72% | 11.76% | 26.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.20% | 2.21% | -1.51% | 7.50% | 34.08% |
| Operating Income | -21.20% | -2.21% | 1.51% | -7.50% | -34.08% |
| Income Before Tax | -127.73% | -62.70% | -80.95% | -4.69% | -13.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -127.73% | -62.70% | -80.95% | -4.69% | -13.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -127.73% | -62.70% | -80.95% | -4.69% | -13.94% |
| EBIT | -21.20% | -2.21% | 1.51% | -7.50% | -34.08% |
| EBITDA | -21.26% | -2.23% | 1.40% | -7.65% | -34.53% |
| EPS Basic | -97.88% | -55.42% | -70.91% | 4.74% | -1.00% |
| Normalized Basic EPS | -97.89% | -55.55% | -71.01% | 4.70% | -1.00% |
| EPS Diluted | -125.40% | -73.70% | -73.07% | 2.72% | -3.03% |
| Normalized Diluted EPS | -97.54% | -55.49% | -71.01% | 4.70% | -1.00% |
| Average Basic Shares Outstanding | 12.85% | 6.36% | 7.06% | 10.00% | 13.47% |
| Average Diluted Shares Outstanding | 13.32% | 6.70% | 7.06% | 10.00% | 13.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |